An Escherichia coli library comprising 8,424 strains incorporating gene fragments of the equol-producing bacterium Slackia sp. strain NATTS was constructed and screened for E. coli strains having daidzein-and dihydrodaidzein (DHD)-metabolizing activity. We obtained 3 clones that functioned to convert daidzein to DHD and 2 clones that converted DHD to equol. We then sequenced the gene fragments inserted into plasmids contained by these 5 clones. All of the gene fragments were contiguous, encoding three open reading frames (ORF-1, -2, and -3). Analysis of E. coli strains containing an expression vector incorporating one of the orf-1, -2, or -3 genes revealed that (i) the protein encoded by orf-1 was involved in the conversion of cis/trans-tetrahydrodaidzein (cis/trans-THD) to equol, (ii) the protein encoded by orf-2 was involved in the conversion of DHD to cis/trans-THD, and (iii) the protein encoded by orf-3 was involved in the conversion of daidzein to DHD. ORF-1 had a primary amino acid structure similar to that of succinate dehydrogenase. ORF-2 was presumed to be an enzyme belonging to the short-chain dehydrogenase/reductase superfamily. ORF-3 was predicted to have 42% identity to the daidzein reductase of Lactococcus strain 20-92 and belonged to the NADH:flavin oxidoreductase family. These findings showed that the daidzein-to-equol conversion reaction in the Slackia sp. NATTS strain proceeds by the action of these three enzymes.S oybean isoflavones and their derivatives have been reported to prevent sex hormone-dependent diseases, such as prostate cancer, breast cancer, menopausal disorders, premenstrual syndrome, and osteoporosis (3,9,10,16,21,30). The isoflavone equol is expected to prevent hormone-dependent diseases, such as prostate cancer, because of its ability to bind to dihydrotestosterone and its high capacity to bind to estrogen receptor ; moreover, it is the most potent antioxidant of all the isoflavones (1, 2, 5, 17, 23).To date, several bacteria capable of producing equol have been isolated from human or animal feces (18-20, 29, 31). Many of these strains are suggested to first metabolize daidzein as a substrate to dihydrodaidzein (DHD) and to then metabolize DHD to equol. Recently, daidzein reductase, which converts daidzein to DHD, has been purified from the equol-producing Lactococcus strain 20-92 (25). On the other hand, it has been suggested that, in the Eggerthella strain Julong 732, DHD is converted to equol by the production of cis/trans-tetrahydrodaidzein (cis/trans-THD) as an intermediate metabolite (13,14). These studies have therefore suggested that daidzein is converted to equol via DHD and cis/ trans-THD. However, the details of the enzymes involved in the production of equol from daidzein, and of the genes encoding them, remain largely unknown.We have recently isolated Slackia sp. strain NATTS, which has potent daidzein-to-equol conversion ability, from healthy human feces (26). This strain has a more potent daidzein-equol conversion activity than the other equol-producing strains...